Clinical Trials Logo

Adenocarcinoma of the Stomach clinical trials

View clinical trials related to Adenocarcinoma of the Stomach.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04878783 Active, not recruiting - Gastric Cancer Clinical Trials

Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG

Start date: December 20, 2019
Phase:
Study type: Observational

The aim of this study is to develop a CT scan-based radiomics predictive model about tumor regression grade (TRG) in patients with esophago-gastric junction (EGJ) ang gastric cancer undergoing perioperative chemotherapy. The molecular expression of the neoplasms will be evaluated to assess its association with the TRG and the radiomic features.

NCT ID: NCT03647969 Active, not recruiting - Clinical trials for GastroEsophageal Cancer

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Start date: November 7, 2018
Phase: Phase 2
Study type: Interventional

Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be treated with modified FOLFOX, with modified FOLFOX plus Nivolumab and Ipilimumab or FLOT plus Nivolumab. The groups will be compared for time until progression of the disease (primary endpoint) as well as for response to the treatment, overall survival, safety/tolerability of the treatment and quality of life.

NCT ID: NCT02202759 Active, not recruiting - Clinical trials for Adenocarcinoma of the Stomach

A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction

Start date: July 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.

NCT ID: NCT01095120 Active, not recruiting - Clinical trials for Adenocarcinoma of the Stomach

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Start date: March 2010
Phase: Phase 2
Study type: Interventional

Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric cancer.